Free Submission Public Relations &
Deutsch English

Analgesics in the US

US analgesics market: $4.3 billion industry in 2012

Print article Print article
2014-02-24 09:37:01 - Analgesics in the US - a new market research report on

Pfizer led the US analgesics market on the strength of ibuprofen brand Advil, which commanded 15% value share in 2012. Given its high level of brand recognition, Advil was historically a strong, but distant, second to McNeils Tylenol in share. Tylenol, however, steadily haemorrhaged share since the onset of the McNeil recalls in 2010. While private label captured much of these sales, Advil gained three percentage points in share since 2009. Likewise, second ranked company Bayer Corp witnessed modest gains for naproxen brand Aleve, as well as Bayer Aspirin.

The US sought to alleviate liver concerns related to acetaminophen under guidance from the Food and Drug Administration (FDA) issued in July 2012. While the FDA already requires products containing the ingredient



to include a liver injury warning on the label, the new guidelines clarify what constitutes as an overdose, allowing certain products to specify 4,000mg versus ―maximum daily dose.‖ The distinction is significant, as the daily dose of many products is safely under the 4,000mg toxicity level.

The McNeil and Novartis recalls will continue to be a major factor moving into the forecast period. Both companies have delayed estimates of when shuttered manufacturing facilities will be fully operational again, in McNeils case multiple times. Many recalled products are still not back on store shelves, and some retailers, such have CVS, have announced that they will change how they stock Tylenol products as a result.

Key Headlines

- Current retail value sales of analgesics grow by 2% to reach US$4.3 billion in 2012
- Major recalls from Novartis and ongoing manufacturing issues at McNeil boost private label
- Relatively immune from recalls and supported by the elderly population, topical analgesics/anaesthetic jumps by 12% in current value terms in 2012
- Pfizer Consumer Healthcare Inc continues to build on lead with 15% value share in 2012
- As recalled brands return, analgesics is expected to recover by a constant value CAGR of 1% over the forecast period

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact